New Covid Variant Eris: A Lancet Study on Immunity Escape

In recent times, the world has been grappling with various strains of the SARS-CoV-2 virus, and the emergence of new variants has raised concerns about their impact on immunity. A Lancet study sheds light on one such variant, EG.5.1, also known as Eris, and its unique ability to escape immunity, though it’s not necessarily more infectious than its predecessors.

Understanding EG.5.1: The Lancet Study

The Background

Since May of this year, EG.5, including its descendant EG.5.1, has been on the rise in many countries. The World Health Organization (WHO) has classified this lineage as a “Variant of Interest,” referring to it as Eris. This Lancet study aimed to examine the characteristics of EG.5.1 and determine whether it poses a significant threat to our immunity.

Not More Infectious, but a Better Immunity Escaper

The researchers found that EG.5.1 is not inherently more infectious than previous SARS-CoV-2 lineages, meaning it cannot infect host cells more effectively. This is reassuring news as it implies that EG.5.1 doesn’t have a heightened ability to spread.

Immunity Escape

However, the real concern lies in EG.5.1’s ability to escape immunity. Our immune protection against COVID-19 relies in part on neutralizing antibodies produced by our immune system after vaccination or infection. These antibodies attach to the spike protein of SARS-CoV-2, preventing the virus from entering our cells, a mechanism known as neutralization.

The Lancet study found that EG.5.1 is less effectively neutralized by antibodies present in the blood of vaccinated individuals or those who have both been vaccinated and infected. This suggests that EG.5.1 has an advantage in infecting individuals whose immune systems have produced neutralizing antibodies.

Moderate Immunity Evasion

It’s important to note that while EG.5.1 does have an increased ability to escape antibodies, this enhancement is moderate. It is by no means sufficient to completely undermine the immunity established through vaccination or prior infection. This finding offers a glimmer of hope in the ongoing battle against the virus.


In conclusion, the Lancet study on the EG.5.1 variant, also known as Eris, reveals that while it may not be more infectious than its predecessors, it possesses a moderate ability to escape immunity. This underscores the importance of continued vigilance in our efforts to combat COVID-19. It’s crucial to adapt vaccination strategies and stay informed about the evolving nature of the virus.


  1. Is EG.5.1 more dangerous than other variants?
    • EG.5.1 is not necessarily more dangerous in terms of infectivity but has a moderate ability to escape immunity.
  2. Should I be concerned about Eris if I’m vaccinated?
    • While EG.5.1 can partially evade immunity, vaccines still provide significant protection against severe illness.
  3. What can I do to protect myself from EG.5.1?
    • Continue following public health guidelines, including vaccination and mask-wearing, to reduce the risk of infection.
  4. Is Eris the dominant variant now?
    • Eris has been on the rise but may not be the dominant variant in all regions.
  5. How can researchers combat variants like EG.5.1?
    • Ongoing research and adaptation of vaccines will be essential in addressing such variants.

For the latest updates on COVID-19 and variants, access reliable information here. Stay safe and informed.